Hyderabad-based pharmaceutical giant Dr. Reddy’s has launched Toripalimab in India, targeting patients with nasopharyngeal carcinoma (NPC), a rare and aggressive form of head and neck cancer. This immuno-oncology drug is the first of its kind to be approved by leading regulatory bodies, including the USFDA, EMA, and MHRA, for the treatment of recurrent or metastatic NPC (RM-NPC) in adults.
How Toripalimab works
Toripalimab, an anti-PD-1 monoclonal antibody, works by blocking interactions between the PD-1 receptor and its ligands, PD-L1 and PD-L2. This mechanism enhances the immune system’s ability to recognize and destroy tumor cells by promoting improved receptor internalization.
The drug’s launch in India follows Dr. Reddy’s 2023 licensing and commercialization agreement with Shanghai Junshi Biosciences, granting the company exclusive rights to develop and market Toripalimab in 21 countries, including India, South Africa, and several Latin American nations.
Addressing a critical need in India
India is among the top five countries globally in terms of NPC burden. According to GLOBOCAN 2022, the country reported 6,519 new NPC cases, with the northeastern states, particularly Kohima in Nagaland, showing the highest incidence rates.
MV Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy emphasized the importance of this launch:“The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma in India.”
He added that Toripalimab has shown superior outcomes for RM-NPC compared to the existing standard of care, addressing an urgent need for advanced treatment options.
A new standard in NPC treatment
Before Toripalimab, chemotherapy with gemcitabine and cisplatin was the primary treatment for RM-NPC in India. Now, Toripalimab, when combined with these drugs, is approved as a first-line therapy, offering a 48% reduction in the risk of disease progression or death. It is also approved as a monotherapy for patients with recurrent or metastatic NPC who have failed platinum-based chemotherapy.
Dr. Reddy’s commitment to cancer care
Dr. Reddy’s aims to create a comprehensive ecosystem of cancer care. This includes access to innovative formulations, strategic collaborations, and supportive initiatives such as nutrition and digital tools. The company’s oncology portfolio also features Reditux, Versavo, Lenangio, and Hervey Cta, catering to a wide range of cancer treatments.
